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Abstract
Background: A number of registry studies have reported suboptimal adherence to guidelines for cardiovascular
prevention during the first year after acute myocardial infarction (AMI). However, only a few studies have addressed
long-term secondary prevention after AMI. This study evaluates prevention guideline adherence and outcome of
guideline-directed secondary prevention in patients surviving 2 years after AMI.
Methods: Patients aged 18–85 years at the time of their index AMI were consecutively identified from hospital
discharge records between July 2010 and December 2011 in Gothenburg, Sweden. All patients who agreed to
participate in the study (16.2%) were invited for a structured interview, physical examinations and laboratory
analysis 2 years after AMI. Guideline-directed secondary preventive goals were defined as optimally controlled
blood pressure, serum cholesterol, glucose, regular physical activity, smoking cessation and pharmacological
treatment.
Results: The mean age of the study cohort (n = 200) at the index AMI was 63.0 ± 9.7 years, 79% were men. Only
3.5% of the cohort achieved all six guideline-directed secondary preventive goals 2 years after infarction. LDL
< 1.8 mmol/L was achieved in 18.5% of the cohort, regular exercise in 45.5% and systolic blood pressure
<140 mmHg in 57.0%. Anti-platelet therapy was used by 97% of the patients, beta-blockers by 83.0%, angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers by 76.5% and statins by 88.5%. During follow-up, non-
fatal adverse cardiovascular events (cardiac hospitalization, recurrent acute coronary syndrome, angina pectoris, new
percutaneous coronary intervention, new onset of atrial fibrillation, post-infarct heart failure, pacemaker
implantation, stroke/transient ischemic attack (TIA), cardiac surgery and cardiac arrest) occurred in
47% of the cohort and readmission due to cardiac causes in 30%.
Conclusions: Our data showed the failure of secondary prevention in our daily clinical practice and high rate of
non-fatal adverse cardiovascular events 2 years after AMI.
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Background
The main purpose of secondary prevention after acute
myocardial infarction (AMI) is to reduce recurrence,
decrease morbidity and mortality and improve quality of
life. To achieve these goals, available guidelines for cardio-
vascular prevention worldwide uniformly recommend life-
style interventions: smoking cessation, increased physical
activity, maintaining a healthy body mass index (BMI),
optimal control of risk factors (blood pressure, cholesterol
and glucose control) and optimal use of cardio protective
drug therapies (aspirin, beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors/angiotensin II recep-
tor blockers (ARBs), lipid-lowering drugs) [1–5].
During the past decades, several studies have repeat-
edly demonstrated suboptimal adherence to guidelines
in patients after AMI. EUROASPIRE (European Action
on Secondary and Primary Prevention by Intervention to
Reduce Events) I-IV surveys showed that a large majority
of coronary artery disease patients did not achieve the
standard of secondary prevention stipulated by the
guidelines (1–5). The prevalence of smoking, poor diet
and physical inactivity remains high and most patients
remain overweight or obese with a high prevalence of
diabetes. Moreover, despite increasing use of medica-
tions, risk factor control remains suboptimal [6–8]. A
recent Swedish study showed that risk factor control has
improved slightly over time after AMI, but improvement
was mainly seen in control of blood pressure, indicating
substantial potential for improvement in other prevent-
ive goals [9, 10].
Persistent secondary prevention is warranted after
AMI for long-term cardiovascular protection. However,
available studies that have evaluated secondary preven-
tion have mainly been done up to within 1 year post
AMI. Moreover, most studies have been registry-based,
where data are often restricted and less detailed. Conse-
quently, knowledge about secondary prevention 2 years
post-AMI is limited. The main objectives of the current
study were therefore to evaluate adherence to secondary
prevention guidelines and outcome 2 years after AMI.
Methods
Patients
We included consecutive men and women who had under-
gone AMI, were aged ≥18 years and <85 years at the time
of their index event and who were still alive 2 years
post-AMI. The patients were identified retrospectively from
hospital discharge lists. All participants were living in the
catchment area of Gothenburg and had been hospitalized
for AMI at Sahlgrenska University Hospital Östra or
Sahlgrenska University Hospital/Sahlgrenska between July
2010 and December 2011. The diagnosis of AMI was based
on the following criteria: at least one value of troponin level
>15 ng/L and at least one of the following: chest pain,
newly discovered ECG changes (pathological ST/T-wave,
left bundle branch block or a pathological Q-wave),
regional wall motion abnormality in the left ventricle
discovered by echocardiography or MRI or proven intracor-
onary thrombosis or stenosis by coronary angiography [11].
Patients unable to speak or understand Swedish were
excluded.
Structured interview
A personal interview was conducted by experienced
nurses at a minimum of 2 years after the index AMI
event. A detailed questionnaire containing pre-defined
questions was used that included information on marital
status, living situation, education, occupation, past ill-
nesses, chest pain and shortness of breath, depression,
medication, smoking, use of Swedish snus, alcohol use,
stress and exercise. The questionnaire was completed
under supervision of the research staff.
Higher education was defined as having a university
degree. Employment was coded dichotomously (working or
not working). Smoking was defined as never smoked; yes,
regularly; yes, sometimes; no, quit smoking. Quit smoking
was defined as trying to quit during the 2 weeks preceding
the interview. Depression was defined as feeling depressed
for more than 2 consecutive weeks during the past
12 months. Self-perceived stress was defined as permanent
stress during the last 5 years [12] Self-reported physical ac-
tivity during leisure time was categorized into four levels
according to a modified version of Saltin-Grimby Physical
Activity Level Scale (SGPALS) [13]: sedentary; moderate
physical activity at least 2 h per week (without sweating);
regular physical activity (1–2 times per week); vigorous
physical activity for at least 3 times per week.
Structured examinations
A variety of variables were measured, including height,
weight, waist circumference, hip circumference, blood
pressure and ECG. Body height was measured to the
nearest ½ cm and weight to 0.1 kg (Tanita Corporation,
Tokyo, Japan), with the subjects in light clothing and
without shoes. BMI was calculated as weight (kg)/height
(m) squared. Waist was defined as the area between the
iliac crest and to the approximate area of the lowest rib.
Hip circumference was measured as the widest circum-
ference around the hips. Resting ECG was taken with a
12-lead ECG (Cardiolex, Solna, Sweden). Blood pressure
was measured twice for each person after a 5-min rest
with the person in a sitting position using the Omron
HEM-907 IntelliSense professional digital blood pressure
monitor (Omron Corporation, Omuro, Kyoto, Japan).
Laboratory analyses
Fasting blood samples were collected for analysis of
hemoglobin, low-density lipoprotein (LDL) cholesterol,
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high-density lipoprotein (HDL) cholesterol, total triglycer-
ides, total serum cholesterol, ApoB/ApoA1 ratio, glycated
hemoglobin HbA1c, blood glucose, potassium, sodium and
creatinine. HbA1c was measured in all participants because
HbA1C is widely accepted as one of diagnostic criteria for
diabetes. As long as patients have HbA1c < 48 mmol/mol
they have achieved goals regardless of diabetes or not.
Serum and plasma were aliquoted and stored at a −80 °C
until analysed. All laboratory analyses were done at the
Department of Clinical Chemistry, Sahlgrenska University
Hospital, Gothenburg, Sweden.
Data from medical records
A retrospective review of medical records was conducted
to collect data on demographic details, medical history,
diagnostic test results (e.g., ECG, echocardiography and
coronary angiogram), treatments and outcome data.
Outcome measures
The primary outcome measure was the proportion of
patients with AMI who achieved the stipulated second-
ary preventive guideline recommendations, categorized
as six variables (Table 1). The secondary outcome meas-
ure was non-fatal adverse cardiovascular events 2 years
after AMI.
The definitions for achieving a guideline standard are
presented in Table 1 [3]. Non-fatal cardiovascular events
were defined as all cardiovascular events that occurred
after the index AMI, including recurrent acute coronary
syndrome, angina pectoris, new onset of atrial fibrilla-
tion, post-MI heart failure, percutaneous coronary inter-
vention (PCI), cardiac arrest, stroke/TIA and any
readmission secondary to cardiac disease. Post-MI heart
failure was defined as a newly developed clinical
manifestation of heart failure based on heart failure
symptoms in combination with either increased NT pro
BNP >300 pg/ml or LVEF <40% after AMI. Angina
pectoris was defined as ≥ class 2 based on the Canadian
Cardiovascular Society Angina Grading Scale (CCS
Angina Grading Scale) [14]. Cardiac readmissions
were all readmissions due to any cardiac cause (ac-
cording to The International Classification of Diseases
ICD-10).
Statistical analyses
Data are reported as frequency and percentage for cat-
egorical variables and mean with standard deviation for
quantitative variables. Data were analysed using IBM
SPSS Statistics 22.0 (IBM Corp., Chicago, ILL, USA).
Ethics
This study complies with the Declaration of Helsinki
[15] and the study protocol was approved by the Ethics
Committee of the Medical Faculty of the University of
Gothenburg. Written informed consent was obtained
from each participant by the principal investigator. The
research assistants signed the Case Report Form to con-
firm that informed consent was obtained.
Results
Study cohort
In total, 1234 patients were hospitalized with an AMI in
the area of Gothenburg between July 2010 and December
2011. Of those 1234 patients, 860 were excluded from the
study because of various reasons (Fig. 1). After excluding
all participants that either did not meet the inclusion
criteria, or who could not be accessed, 374 patients were
eligible. Of those, 56 patients did not sign the informed
consent form or declined further participation and 118
did not respond to the invitation. Thus, the final sample
included 200 patients (Fig. 1).
Table 1 Secondary prevention guidelines after AMI
1 Optimally controlled blood pressure, defined
as SBP <140 mmHg
2 Optimally controlled cholesterol levels, defined
as LDL cholesterol <1.8 mmol/L
3 Optimally controlled glucose, defined as HbA1c
<48 mmol/mol
4 Regular physical activity that caused sweating
at least two times a week
5 Smoking cessation, defined as non-smoking
at the time of the interview
6 Pharmacological treatment with ACE inhibitors
or ARBs
AMI acute myocardial infarction, SBP systolic blood pressure, LDL low-density
lipoprotein, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers
Fig. 1 Study flow chart
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Baseline characteristics at the time of the index AMI
At the time of the index AMI, 69% of the patients had
ST-segment elevation myocardial infarction (STEMI),
31% a non–STEMI (NSTEMI). Mean heart rate was 75.6
(SD ±18.8) beats/min, mean systolic blood pressure
(SBP) 146.1 (SD ±25.7) mmHg and mean diastolic blood
pressure (DBP) 91.3 (SD ±15.0) mmHg. Almost every-
one that was included (96%) underwent a percutaneous
coronary intervention (PCI) or a coronary artery bypass
grafting (CABG) in association with the index event.
Demographic characteristics at interview
The mean age of the study cohort at follow-up (n = 200)
was 65.5 (SD ±9.8) years and 79% were male (Table 2).
Moreover, 79.3% were born in Sweden, 23.5% had a
higher education and 34.4% were still actively working.
Lifestyle characteristics and psychological conditions at
interview
As shown in Table 2, a minority of the patients were still
smokers (12.5%) regularly or occasionally; however, most
of these patients had smoked at some time in their life
(69%). Only one of seven patients reported a sedentary
lifestyle 2 years after their index AMI, whereas 40.5%
claimed to engage in moderate physical exercise without
sweating, 25% did moderate exercise with sweating and
20.5% participated in regular physical exercise and train-
ing. Concerning psychological factors, 15% of the patients
had been depressed during the past year and almost 10%
had felt constantly stressed during the past 5 years. Feeling
stressed and depressed were more common in those aged
<65 years. Almost 20% of the patients <65 years of age
had been constantly stressed for the past 5 years, whereas
only 2% of those aged >65 years had felt stressed during
the same period.
Clinical characteristics based on interview, review of
medical records and physical examinations
The two most common comorbidities were hypertension
(63.4%) and hyperlipidemia (63.9%), followed by diabetes
mellitus (21.8%) and atrial fibrillation (14.8%). Medical
records showed that 22.5% of the patients were still
smoking at the time of the index AMI, 13% had at least
one previous myocardial infarction and 11.5% underwent
PCI (Table 2).
At the physical examination, which was given during
the interview, mean SBP was 137.5 mmHg and mean
DBP 79.6 mmHg respectively (Table 3). Sinus rhythm
constituted 93% with a mean heart rate at approximately
59.0 beats/minute. 17.5% of the study population had a
BMI over 30 kg/m2
Table 2 Social and clinical characteristics of patients at the time








Age, years, mean ± SD 65.5 ± 9.8 64.7 ± 9.5 68.2 ± 10.2
Social factors
Born in Swedena
n = 199 (%)
158 (79.3) 123 (77.8) 35 (83.3)
Higher educationa
n = 200 (%)
47 (23.5) 35 (22.2) 12 (28.6)
Currently workinga
n = 199 (%)
72 (34.4) 62 (39.2) 10 (23.8)
Smokinga n = 200
Never (%) 62 (31.0) 45 (28.5) 17 (40.5)
Regularly (%) 13 (6.5) 13 (8.2) 0 (0.0)
Sometimes (%) 12 (6.0) 11 (7.0) 1 (2.4)
Quit (%) 113 (56.5) 89 (56.3) 24 (57.1)
Exercisea n = 200
Sedentary n (%) 28 (14) 18 (11.4) 10 (23.8)
Moderate activity n (%) 81 (40.5) 63 (39.9) 18 (42.9)
Regular activity n, (%) 50 (25.5) 41 (35.9) 9 (21.4)
Vigorous activity n, (%) 41 (20.5) 36 (22.8) 5 (11.9)
Cardiovascular diseases
Atrial fibrillationa
n = 196 (%)
29 (14.8) 19 (12.3) 10 (24.4)
Known heart failurea
n = 193 (%)
16 (8.3) 10 (6.5) 6 (15.8)
Hypertensiona
n = 194 (%)
123 (63.4) 93 (61.2) 30 (71.4)
Diabetesa n = 197 (%) 43 (21.8) 37 (23.6) 6 (15)
Stroke/TIAa n = 198 (%) 14 (7.2) 12 (7.7) 2 (4.9)
Hyperlipidemiaa
n = 180 (%)
115 (63.9) 90 (63.4) 25 (65.8)
Previous MI n = 200 (%) 26 (13.0) 19 (12.0) 8 (19.0)
Previous PCI n = 200 (%) 23 (11.5) 18 (11.4) 5 (11.9)
Non-cardiovascular disease
Cancera n = 200 (%) 31 (15.5) 22 (13.9) 9 (21.4)
COPD n = 193 (%) 39 (20.2) 29 (19.1) 10 (24.4)
OSA n = 162 (%) 48 (29.6) 37 (29.6) 11 (29.7)
Renal failure GFR < 60
n = 200 (%)
55 (27.5) 33 (20.1) 18 (42.9)
Renal failure GFR < 30
n = 200 (%)
4 (2) 4 (2.5) 0 (0.0)
Depressed for at least
2 consecutive weeks in the
past 12 monthsa n = 200 (%)
30 (15) 20 (12.7) 10 (23.8)
Data were presented as n (%)
TIA transient ischemic attack, MI myocardial infarction, PCI percutaneous
coronary intervention, COPD chronic obstructive pulmonary disease, OSA
obstructive sleep apnea
aSelf-specified answers to questions in the SEPAT questionnaire
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Non-fatal cardiovascular events
During the 2-year study period non-fatal cardiovascular
events occurred in 46.5% of the participants. Readmis-
sions due to all causes were 50.5% and due to cardiac
disease 30%. Among them, new AMIs constituted 8%,
new PCIs 11.5%, atrial fibrillation 7.5%, TIA/stroke 6%,
cardiac arrest 1%, post-infarction heart failure 19.5% and
cardiac surgery 9.5% (Table 4). It is noteworthy to
mention that the number of cardiac events may out-
number readmission rate since several events may occur
during the same readmission. Our study was not
powered to assess the causal relation between increased
non-fatal cardiovascular events and suboptimal second-
ary prevention.
Achievements of guideline standards in secondary
prevention
As shown in Table 5, the goal of SBP was achieved in
57% of the patients, 18.5% had LDL of <1.8 mmol/L,
87.5% did not smoke, 45.5% achieved the goal defined by
regular exercise with sweating. The goal for HbA1c was
achieved in almost 90% of the patients; however, most of
these patients did not have diabetes. ACE inhibitor/ARB
medication was administered to 75% of the patients. For
other medications, 96% of the patients were treated with
antiplatelet medicines, 83.0% with beta-blockers and
88.5% with statins. Only 3.5% of the whole study cohort
achieved all six secondary preventive goals 2 years after
AMI (Tables 5, 6, and Fig. 2).
Development of risk profile 2 years after AMI
As shown in Table 5, there were more individuals that
reached the goals of secondary prevention 2 years after
the index AMI than at the time of AMI in terms of
smoking, LDL reduction, blood pressure control and
physical activity (Table 5). Moreover, there was a
tendency towards increased BMI 2 years after the index
AMI. The proportion of patients with BMI >30 kg/m2
increased from 17.5% at the time of the index AMI to
25.5% 2 years later.
Discussion
In the present study the six secondary preventive goals
were achieved by only 3.5% of the patients 2 years after
the AMI event. Adherence to cardio-protective
Table 3 Physical examination and laboratory analysis at the








SBP (mmHg) 137.5 (18) 138.3 (18.3) 134.2 (16.4)
DBP (mmHg) 79.6 (10.3) 80.7 (10.0) 75.5 (10.5)
HR (beats/minute) 59.7 (10.7) 59.1 (10.8) 61.9 (10.2)
Weight (Kg) 84.7 (16.2) 86.9 (15.4) 76.4 (16.3)
BMI
25 kg/m2 < BMI
≤30 kg/m2 (%)
47.0 50.6 35.7
> 30 kg/m2 (%) 25.5 20.9 40.5
Waist (cm) 100.2 (12.4) 101.4 (11.0) 95.7 (16.1)
Lab
HbA1c (mmol/L) 40.5 (9.3) 39.8 (8.8) 43.0 (10.5)
Cholesterol (mmol/L) 4.1 (1.0) 4.1 (0.9) 4.5 (1.2)
LDL (mmol/L) 2.4 (0.9) 2.4 (0.8) 2.6 (1.1)
HDL (mmol/L) 1.4 (0.6) 1.4 (0.4) 1.6 (0.5)
ApoB/ApoA1 quote 0.6 (0.2) 0.6 (0.2) 0.5 (0.2)
Triglycerides (mmol/L) 1.3 (0.6) 1.3 (0.6) 1.3 (0.5)
P-glucose (mmol/L) 5.7 (1.3) 5.7 (1.3) 5.7 (1.3)
NTproBNP (pg/ml) 396.8 (750.7) 344.1 (682.3) 594.9 (949.6)
NTproBNP
> 300 pg/ml (%)
31.5 25.3 44.2
Data were presented as n (%), otherwise in mean (SD). SBP systolic blood
pressure, DBP diastolic blood pressure, HR heart rate, BMI body mass index,
LDL low density lipoprotein, HDL high density lipoprotein
Table 4 Non-fatal cardiovascular events during the 2-year
follow-up after the index AMI event
Readmissions, all cause, n (%) 101 (50.5)
Readmissions, cardiac, n (%) 60 (30.0)
Recurrent myocardial infarction, n (%) 16 (8.0)
Unstable angina, n (%) 8 (4.0)
PCI, n (%) 23 (11.5)
Cardiac surgery, n (%)a 19 (9.5)
Cardiac arrest, n (%) 2 (1.0)
Stroke/TIA, n (%) 9 (4.5)
Post-MI heart failure, n (%) 40 (20.0)
Post-MI atrial fibrillation, n (%) 15 (7.5)
Angina pectoris CCS ≥2, n (%) 34 (17.0)
AMI acute myocardial infarction, PCI percutaneous coronary intervention, TIA
transient ischemic attack, MI myocardial infarction, CCS Canadian
Cardiovascular Society
acardiac surgery: all surgical procedure related to heart except percutaneous
coronary intervention
Table 5 Development of a risk profile at the time of AMI and at
the 2-year follow-up interview
At AMI At the 2-year
follow-up interview
No smoking n (%) 155 (77.5) 175 (87.5)
LDL cholesterol <1.8 mmol/L n (%) 8 (4) 37 (18.5)
HbA1C <4.8 mmol/mol n (%) NA 177 (88.5)
SBP <140 mmHg n (%) 152 (76) 114 (57)
Regular exercise training n (%) NA 90 (45.5)
NA not available, AMI acute myocardial infarction, LDL low density lipoprotein,
SBP systolic blood pressure
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medications, however, was generally good. Still, non-fatal
cardiovascular events occurred in 46.5% of the cohort and
cardiac readmissions in 30% at the 2-year follow-up.
Our study is an extension of the EUROASPIRE survey
and the Secondary Prevention after Heart Intensive Care
Admission (SEPHIA) Registry in Sweden. EUROASPIRE
IV was a cross-sectional study carried out in 24 European
countries. Patients included in that study were those with
either acute coronary syndrome or elective revasculariza-
tion in the form of balloon angioplasty or coronary artery
surgery. The starting date for identification of an event
was ≥ 6 months and < 3 years before the expected date of
the study interview [8]. The SEPHIA Registry is an
on-going Swedish quality registry of AMI patients that
focuses on four preventive goals (smoking cessation, opti-
mal control of blood pressure, cholesterol and glucose)
and data on the patients are collected during the first year
after an AMI. Patients older than 75 years of age are not
included in the Registry. Patients are invited to be inter-
viewed by either a registered nurse or physician during an
outpatient visit or via a telephone call on two occasions:
4–10 weeks (mean 56 days) and 12–14 months (mean
399 days) after myocardial infarction [9].
Our findings extended available observations by show-
ing divergent development of risk factors from short-
term to long-term time frame after AMI. Firstly, our
study confirmed some observations from previous short-
term studies. For instance, regular physical activity is a
secondary preventive goal that may be hard to achieve.
In the EUROASPIRE IV survey only 40% of the partici-
pants attained a physical vigorous intensity level for at
least 20 min one or more times per week [8]. In Sweden,
the overall participation rate in exercise training within
cardiac rehabilitation programs 1 year post-AMI is 51%
[9]. Two years after AMI, 45.5% of our patients reported
participating in moderate regular exercise that caused
them to perspire. Thus, it appears that, as in the rest of
Europe, a comparable number of our Swedish patients
with coronary artery disease participate in cardiac re-
habilitation. Furthermore, in our study physical exercise
during leisure activity was comparable with that ob-
served in the EUROASPIRE IV. Another example is
smoking habit. Regrettably, despite that smoking cessa-
tion reduces the risk of a new myocardial infarction [16],
about one third of the patients still smoked in EUROAS-
PIRE IV survey study [8]. A similar trend was seen in
the Swedish myocardial infarct registry [9] 1 year after
the index AMI. Our study suggests that there is an
improvement in the number of patients who quit smoking
from the index AMI, since 87.5% of the study participants
were classified as non-smokers 2 years after AMI. How-
ever, it is not clear whether the improved smoking cessa-
tion rate observed in our cohort could be attributed to an
increase in the death rate in those patients that did con-
tinue smoking but did not survive long enough to be
invited. The better results could therefore simply reflect a
selection bias in our cohort because participation rates
were low. Finally, guideline-directed medical therapy and
glucose control 2 years after AMI were in accordance with
those reported in EUROASPIRE IV [8] and SEPHIA [9],
except that double anti-platelet therapy was indicated only
1 year after AMI and thus could not be adequately evalu-
ated after 2 years.
Secondly, our study provided new information about
negative developments in some risk factors from previ-
ous short-term studies. Compared with SEPHIA (9), our
findings demonstrated failure of long-term secondary
prevention as shown by decreased goal achievement in
LDL <1.8 mmol/L from 51% in SEPHIA to 18,5% in our
study, and in blood pressure control with SBP of
<140 mmHg from 73% in SEPHIA to 57% in our study,
notwithstanding that guideline-directed medical therapy
were similar regardless of short or long term after AMI.
However, caution must be taken because two studies are
not fully comparable.
Limitations
Our study has some limitations. Patients who were too
sick or disabled to attend the study visits could not par-
ticipate. Moreover, patients who did not speak or under-
stand Swedish were excluded. It is possible that this
category of patients may show less compliance and thus
Table 6 Comparison of pharmacological treatments at the time
of the index AMI event and at interview 2 years after AMI
At AMI At interview
Aspirin n = 200 (%) 199 (99.5) 183 (91.5)
Beta-blocker n = 200 (%) 187 (93.5) 166 (83.0)
ACE-inhibitor or Angiotensin
receptor blocker n = 200 (%)
177 (88.5) 153 (76.5)
Statin n = 200 (%) 193 (96.5) 177 (88.5)
Clopidogrel/prasugrel n = 200 (%) 179 (89.5) 11 (5.5)
AMI acute myocardial infarction, ACE angiotensin-converting enzyme
Fig. 2 Number of achieved goals (%) of guideline standard secondary
prevention two years post AMI
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if they had been included, the goal achievements might
have been even lower. Furthermore, in our study, more
STEMI than NTSEMI were included despite NSTEMI
constitutes the majority of ACS. There are two possible
explanations: 1) the majority of the participants (87%) in
our study were hospitalized at Sahlgrenska University
Hospital at the time of their index event, the only
hospital in Gothenburg with round-the-clock service for
PCI, thus more STEMI than NTSEMI were included 2)
many patients with NSTEMI have more co-morbidity
and thus more hospital visits. This might explain why
they were less interested in participating in the study
since it means additional hospitals visits. Finally, we
could not interview the patients who died during the
2 years that passed between the index AMI and the
study inclusion stage. These patients were probably less
compliant with the secondary prevention interventions
than those who were included in the study. Thus, our
results, if anything, may exaggerate the number of per-
sons who potentially achieve secondary prevention goals,
further underlining the fact that much could be gained
in this area with better adherence to guidelines. Finally,
this study was not powered to investigate cause-effect
relationship between cardiovascular events and second-
ary prevention.
Conclusion
Secondary prevention 2 years after AMI proved sub-
optimal in our cohort of patients. Only 3.5% of our
patients attained all six secondary prevention goals.
Therefore, there is considerable potential to raise the
standard of preventive cardiology care through more
effective lifestyle intervention and to more rigorously
control of risk factors. Perhaps most importantly we
need to increase awareness of the current situation
and improve regular follow up. Such an effort should
help to reduce cardiovascular morbidity and mortality
in this patient group.
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